Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Jan 26, 2015

Keywords

ClinConnect Summary

This clinical trial is investigating how certain genetic factors might affect how well patients respond to two different types of medications used to treat atrial fibrillation (AF), a condition that causes irregular heartbeats. The study will involve adults aged 18 and older who experience frequent episodes of AF and are eligible for either Flecainide or Sotalol, which are two types of antiarrhythmic drugs. The goal is to gather initial data that could help in designing a larger study in the future.

If you decide to participate, you'll undergo a series of evaluations to ensure you meet the eligibility criteria, including having a recent heart test that shows AF. While participating, you'll be randomly assigned to try one of the two medications before switching to the other, allowing researchers to compare how effective each drug is for you. It's important to note that this study is currently recruiting participants, and you may not be eligible if you have certain medical conditions or if you've had prior treatments that could affect the results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years of age
• • History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
• • ECG that was recorded within 1 month of randomization showing AF
• • Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
• • Able to give informed consent
• Exclusion Criteria:
• • Permanent AF or isolated atrial flutter
• • Cardiac or thoracic surgery within the previous 6 months
• • Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
• • Medical condition that is likely to be fatal in less than one year
• • A history of prior AF ablation
• • Have already been tried on 2 or more AADs in the past for AF
• • Creatinine clearance \<40 ml/min
• • Left ventricular ejection fraction \< 50%
• • Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI
• • Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc\>480 ms in females and \>460 ms in males at baseline
• • A reversible cause of AF (e.g., hyperthyroidism)
• • Females who are pregnant or nursing
• • History of severe AV node dysfunction unless an electronic pacemaker is present
• • First- or second-degree relative has already participated in the study
• • Unable to adhere to study procedures that are strictly for research purposes